Linear Stapler Versus Circular Stapler in Esophagojejunostomy
Launched by NANCHONG CENTRAL HOSPITAL · May 2, 2022
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the differences between two types of staplers—linear and circular—used during a specific surgical procedure called esophagojejunostomy, which is performed after the complete removal of the stomach (total gastrectomy) for patients with stomach cancer. The goal is to find out which stapler might lead to fewer complications, shorter operative times, and lower hospital costs. Currently, both stapler types are commonly used, but there isn't enough clear evidence to determine which one is better.
To be eligible for this study, participants should have a confirmed diagnosis of stomach cancer at certain stages (T1-T4) and be in generally good health. This means they should have a performance status of 0 or 1, indicating they can carry out normal activities with minimal issues. However, those with advanced cancer that has spread or certain other conditions may not qualify. Participants in the trial can expect to be part of research that may help improve surgical outcomes for future patients with gastric cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Histologically confirmed adenocarcinoma of the stomach, T1-T4 stages.
- • 2. Eastern Cooperative Oncology Group performance status of 0 or 1.
- • 3. Adequate organ function.
- Exclusion Criteria:
- • 1. Patients had distant metastasis.
- • 2. oesophageal invasion of more than 3 cm.
- • 3. Borrmann type 4 or large (more than 8 cm) type 3 carcinoma.
- • 4. Previous chemotherapy or radiation therapy for any other malignancies.
About Nanchong Central Hospital
Nanchong Central Hospital is a leading healthcare institution located in Nanchong, China, dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the hospital combines cutting-edge technology and a skilled team of healthcare professionals to conduct rigorous and ethical clinical research. Nanchong Central Hospital aims to contribute to the global medical community by developing new therapies and enhancing treatment protocols across various therapeutic areas, ensuring the highest standards of patient safety and scientific integrity in all its clinical endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanchong, Sichuan, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials